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Lisbon, Lisbon, PortugalLentiviral vectors (LVs) are excellent tools for gene transfer
into mammalian cells. It is noteworthy that the first gene ther-
apy treatment using LVs was approved for commercialization
in 2017. The G glycoprotein from rhabdovirus vesicular stoma-
titis virus (VSV-G) is the glycoprotein most used to pseudotype
LVs, due to its high efficiency in transducing several cell types
and its resistance to viral vector purification and storage condi-
tions. However, VSV-G expression induces cytotoxicity, which
limits LV production to short periods. As alternative to VSV-G,
g-retrovirus glycoproteins (4070A derived, GaLV derived, and
RD114 derived) have been used to pseudotype both g-retroviral
vectors (RVs) and LVs. These glycoproteins do not induce cyto-
toxicity, allowing the development of stable LV producer cells.
Additionally, these LV pseudotypes present higher transduc-
tion efficiencies of hematopoietic stem cells when compared
to VSV-G. Here, new 4070A-, RD114-TR-, and GaLV-TR-
derived glycoproteins were developed with the aim of
improving its cytoplasmic tail R-peptide cleavage and thus in-
crease LV infectious titers. The new glycoproteins were tested
in transient LV production using the wild-type or the less active
T26S HIV-1 protease. The GaLV-TR-derived glycoproteins
were able to overcome titer differences observed between LV
production using wild-type and T26S protease. Additionally,
these glycoproteins were even able to increase LV titers,
evidencing its potential as an alternative glycoprotein to
pseudotype LVs.Received 6 February 2019; accepted 8 August 2019;
https://doi.org/10.1016/j.omtm.2019.08.001.
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Retroviral vectors can deliver and integrate a gene of interest into a
target cell genome upon cell transduction, allowing a long-term
constitutive expression. In the particular case of lentiviral vectors
(LVs), these are able to promote gene transfer into both dividing
and non-dividing cells,1 potentially presenting lower genotoxicity
than g-retroviral vectors (g-RVs) due to their integration pattern.2,3
These reasons justify the growing number of gene therapy clinical tri-
als using LVs in the past 2 decades with the aim of treating several
disorders.4Molecular Therapy: Methods & Cl
This is an open access article under the CC BY-NLVs may be pseudotyped with heterologous viral glycoproteins
acquiring alternative tropism and specific cell-entry properties.5,6
Generally, the G glycoprotein from rhabdovirus vesicular stomatitis
virus (VSV-G) is used to pseudotype LVs since, the wide distribution
and high molecule number of VSV-G receptors at the cell surface
allow for efficient transduction of several cell types.7–9 Additionally,
LVs pseudotyped with VSV-G can be concentrated by ultracentrifu-
gation without a substantial loss of infectivity and are resistant to
several freeze-thaw cycles, which also contributes for their wide us-
age.6 However, the syncytium formation and consequent cytotoxicity,
both resultant from VSV-G fusogenicity activation in viral producer
cells, do not allow LV production for more than a few days.10–12 The
VSV-G-pseudotyped LVs are usually produced transiently by co-
transfection of 293T cells with LV expression cassettes or constitu-
tively produced by LV producer stable cell lines making use of induc-
ible promoters to drive VSV-G expression.10–12
As alternatives to VSV-G, the amphotropic murine leukemia virus
(4070A), gibbon ape leukemia virus (GaLV), and feline endogenous
retrovirus (RD114) glycoproteins have been used to pseudotype both
g-RVs and LVs.13–22 The production of g-RVs pseudotyped with these
three g-retrovirus glycoproteins do not present major constraints.
However, while the production of LVs pseudotyped with 4070A has
no impact on infectious titers,23–27 the co-expression of HIV-1 core
proteins with GaLV or RD114 glycoproteins barely results in the pro-
duction of infectious LVs.28–32 These titer asymmetries are due to dif-
ferences between cytoplasmatic tail amino-acid sequences of the glyco-
proteins (Figure 1A), since the fully fusogenic activation of 4070A,
RD114, and GaLV is dependent on the cytoplasmatic tail R-peptide
recognition and cleavage by the viral protease.33–42 The replacement
of the RD114 and GaLV cytoplasmic tail region by the one for
4070A (originating the RD114-TR and GaLV-TR, respectively) allowsinical Development Vol. 15 December 2019 ª 2019 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Schematic Representation of Wild-Type and Engineered Viral Envelope Glycoproteins
(A) Amino-acid sequence alignment of glycoprotein cytoplasmic tail: murine leukemia virus (4070A), endogenous feline retrovirus (RD114), and gibbon ape leukemia virus
SEATO strain (GaLV). (B) Amino-acid sequence alignment of the cytoplasmic tail region of the glycoproteins used in LV production and schematic representation of the
envelope expression cassette. The black arrows indicate the protease cleavage site. E, ectodomain; M, transmembrane domain; T, cytoplasmic tail after R-peptide cleavage;
R, R-peptide; CMV, cytomegalovirus promoter; INT, intron; Sp, spacer; pAn, polyadenylation site.
Molecular Therapy: Methods & Clinical Developmenta high increase of LV particle infectivity.19,23,28,29,31,32 Alternatively, just
by replacing the protease cleavage sequence of RD114 with a sequence
naturally cleaved by the HIV-1 protease—namely, the matrix-capsid
cleavage sequence of HIV-1 Gag-Pro-Pol polyprotein (originating
the RDpro glycoprotein)—it is also possible to increase the production
of infectious LV particles.23,30,43
The LVs pseudotyped with the g-retrovirus glycoproteins are able to
transduce several cell types, being particularly efficient in the transduc-
tion of progenitor and differentiated hematopoietic stem cells (HSCs),
when compared to the VSV-G pseudotype.19–22,28 Moreover, these LV2 Molecular Therapy: Methods & Clinical Development Vol. 15 Decembpseudotypes are not inactivated by human serum23,28 and may be
concentrated by ultrafiltration, ultracentrifugation, or tangential flow
filtration.20,44–46 Additionally, the fusogenic activation of these glyco-
proteins should mainly occur after being incorporated into the viral
particles (during viral maturation, when the viral particle buds out of
the cell), preventing syncytium formation, which allows the develop-
ment of stable cell lines able to constitutively produce LVs for several
weeks.43,47–49 Recently, we have established a stable LV producer cell
line using a Gag-Pro-Pol polyprotein with a less active HIV-1 protease
and the 4070A glycoprotein, able to constitutively produce 106 trans-
ducing units (TUs) per milliliter (TU , mL1) for at least 2 months.50er 2019
www.moleculartherapy.orgThe main drawback of pseudotyping LVs with g-retrovirus glycopro-
teins is related to its lower infectious titers when compared to VSV-G
pseudotype.20,23,30,31 In this work, new versions of 4070A, GaLV-TR,
and RD114-TR glycoproteins with modified sequences on the cyto-
plasmic tail were developed with the aim of improving glycoprotein
fusogenicity activation and, consequently, increasing infectious LV
titers. The impact of the modified glycoproteins in viral titers was
assessed by performing transient LV production using either the
wild-type or the mutated less active T26S HIV-1 protease.
RESULTS
Modifications on g-Retrovirus Glycoprotein Cytoplasmic Tail
The amino-acid protease cleavage sequence VQALVLTQ on the
cytoplasmic tail of 4070A, RD114-TR, and GaLV-TR glycoproteins
was replaced by the HIV-1 natural sequence SQNYPIVQ51 or the syn-
thetic sequence GSGIFLETSL,52 originating the glycoproteinpro and
glycoproteinsyntmodified versions, respectively (Figure 1B). A truncated
version of each glycoprotein with the R-peptide sequence deleted was
also developed, the glycoproteinDR, to be used as cleaved glycoprotein
positive control. All the envelope glycoprotein genes were introduced
in the same expression cassette to allow direct comparison between
the different LV pseudotype productions (Figure 1B).
Transient Productions of LV Pseudotypes Using the Wild-Type
Viral Protease
Transient production of third-generation SIN-LVs (self-inactivating
lentiviral vectors) was performed for each pseudotype using the gag-
pro-pol coding the wild-type HIV-1 protease. The supernatant titers
(Transduction Units [TUs] and physical particles [PPs]) were assessed
and compared (Figure 2A). The LV production of 4070A and RD114-
TR pseudotypes generated average titers of about 1.2 107 TU ,mL1
and 1.5 106 TU,mL1, respectively. The new glycoproteinpro and gly-
coproteinsynt versions of 4070A and RD114-TR did not markedly alter
LV titers. However, a decrease in infectious titers was detected for pro-
ductionusing 4070ADR andRD114-TRDR, leading to a 3-fold and 6-fold
decrease in the TU/PP ratio when compared to the production of LVs
pseudotyped with the parental 4070A and RD114-TR, respectively. In
addition to RD114-derived production, the RDpro glycoprotein was
also used, leading to a 3-fold decrease in the TU/PP ratio, when
compared to RD114-TR production. The LV production of GaLV-TR
pseudotype generated a titer of about 1.3  106 TU , mL1. In the
case of GaLV-TR-derived glycoproteins, while the GaLV-TRpro did
not change LV titers, a 2- and 5-fold increment on functional LV titers
were observed for the LV production using GaLV-TRsynt and GaLV-
TRDR glycoproteins, respectively, generating a maximum average titer
of about 6.1 106 TU ,mL1. The LV production of VSV-G pseudo-
type generated an average titer of about 2.8 107 TU , mL1.
Transient Productions of LV Pseudotypes Using the Less Active
T26S Viral Protease
LV production, identical to that described earlier, was also performed
using the gag-pro-polwith the T26Smutated protease (Figure 2B). For
the viral production of 4070A-derived, RD114-derived, and VSV-G
LV pseudotypes, average titer values similar to the ones previouslyMolecular Tobserved were detected. However, for the LV production of GaLV-
TR pseudotype, an average infectious titer of just 1.5 105 TU.mL1
was observed. Nevertheless, infectious titer increases of 9-, 16-, and
35-fold were observed for GaLV-TRpro, GaLV-TRsynt, and GaLV-
TRDR LV-pseudotype production, respectively, generating a
maximum average titer of about 5.3  106 TU , mL1.
Syncytium Formation on 293T Cells Transiently Expressing the
Viral Envelope Glycoproteins
Syncytium formation induced by glycoprotein expression was evalu-
ated in 293T cells transiently transfected with the plasmids coding for
envelope glycoproteins. 24 h post-transfection, cells were observed by
phase-contrast microscopy (Figure 3). Syncytium and non-adherent
round cells were observed in cells transfected with RD114-TRDR,
GaLV-TRDR, and VSV-G expression cassettes. Additionally,
RD114-TRpro expression also led to the formation of few syncytia.
In all the other cases, no major morphological cell differences, relative
to the no expression control, were observed.
DISCUSSION
The 4070A-, RD114-, and GaLV-derived envelope glycoproteins
allow an efficient LV transduction of hematopoietic stem cells,
conferring a more restricted tropism to LVs than VSV-G.19–22,28
Additionally, these glycoproteins can be used as an alternative to
VSV-G in the development of stable constitutive LV producer cell
lines since they are non-cytotoxic.43,47–49 Despite the advantages of
g-retrovirus glycoproteins, the production of LVs pseudotyped with
these usually present lower infectious titer particles when compared
to the production of LVs pseudotyped with VSV-G.
To evaluate whether improved cleavage of the R-peptide in 4070A,
RD114-TR, and GaLV-TR glycoproteins would translate into
increased infectious titers of those LVs pseudotypes, the protease
recognition sequence on the cytoplasmic tail of these glycoproteins
was replaced by two others described to be efficiently cleaved by the
HIV-1 protease: (1) the matrix-capsid natural cleavage sequence
SQNYPIVQ, which is present in the HIV-1 Gag-Pro-Pol polypro-
tein,51 and (2) the GSGIFLETSL synthetic peptide.52 A truncated
version of each glycoprotein without R-peptide was also developed.
These truncated glycoproteins should be produced in their fully fuso-
genic states; thus, it would be expected that the resultant particles
should exhibit the maximum infectious titer for each specific pseudo-
type (if no major interference on glycoprotein cellular traffic and
assembling occurs).
The titer analysis of LV production using the wild-type protease evi-
dences that the engineered 4070A-derived and RD114-TR-derived
glycoproteins did not markedly alter LV titers (Figure 2A). Further-
more, the respective truncated glycoprotein versions (4070ADR and
RD114-TRDR) impaired the production of infectious LVs. Neverthe-
less, the results of RD114-TR and RDpro LV production clearly indi-
cate that RD114-TR is preferable to RDpro for producing higher titers
of infectious LVs. In contrast to 4070A-derived and RD114-TR-
derived glycoproteins, a 3- to 5-fold improvement in titers ofherapy: Methods & Clinical Development Vol. 15 December 2019 3
Figure 2. Transient LV Production Titers with the
Engineered Envelope Glycoproteins
(A and B) Transient production titers of LVs pseudotyped
with 4070A, 4070A-derived, RD114-TR, RD114-TR-
derived, RDpro, GaLV-TR, GaLV-TR-derived, or VSV-G
glycoproteins using the (A) HIV-1 wild-type protease or (B)
HIV-1 T26S protease. The bars represent the transducing
units (TUs), and the circles represent the physical particles
(PPs). The titer values presented are the means ± SD of 3
independent experiments (n = 3). Statistical analysis for the
comparison of LV titers was performed by using an un-
paired Student t test (two-tailed). *p < 0.05; **p < 0.01;
***p < 0.001. The ratios of TUs to PPs are indicated above
each set of LV titers.
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Figure 3. Representative Pictures of HEK293T Cells
Transiently Expressing Envelope Glycoproteins
80 bright-field microscopy. Scale bars, 45 mm.
www.moleculartherapy.orginfectious LVs in relation to the parental glycoprotein (GaLV-TR)
was observed when using the GaLV-TRsynt and GaLV-TRDR glyco-
proteins, leading to a 2-fold increase in the TU/PP ratio. These results
suggest that, unlike for 4070A and RD114-TR pseudotypes, the infec-
tivity of GaLV-TR vectors is limited by an inefficient HIV-1 protease
cleavage of the glycoprotein R-peptide.
The R-peptide cleavage by the viral protease and consequent glyco-
protein fusogenic activation should mainly occur during viral particle
maturation, at the viral budding step (outside of the cell).53,54 This
should allow cellular glycoprotein production, intracellular traf-
ficking, and cell membrane incoorporation in its non-fusogenic
conformation, preventing counterproductive cell interactions.34–37Molecular Therapy: Methods & CIn the specific case of the R-peptide-truncated
glycoproteins developed herein, these are pro-
duced in a fusogenic active state. Thus, once at
the cell-membrane surface, the glycoproteins
will interact with the respective cell receptors of
neighboring cells, promoting cell membrane
fusion and consequent syncytia formation.29,31,41
This may explain the large syncytia observed in
cells transfected with RD114-TRDR and GaLV-
TRDR (Figure 3) and in the respective LV produc-
tion. Nonetheless, unlike for RD114-TRDR, the
syncytia on GaLV-TRDR LV production did not
negatively affect LV titers (Figure 2A).
The impact of protease activity in the production
of several LV pseudotypes was also evaluated by
assessing LV titers obtained from transient LV
production using the HIV-1 gag-pro-pol gene
with the less active T26S mutated protease.55
Comparing the 4070A, RD114-TR, and GaLV-
TR LV production titers of both proteases, it is
possible to observe that the lower activity of
T26S protease affects the production of infectious
LVs. Whereas the less active protease led to
merely a 3- to 4-fold decrease in TU/PP ratio
for 4070A and RD114-TR pseudotypes, a 35-
fold ratio decrease was observed with the
GaLV-TR pseudotype. This decrease was mainly
due to the 10-fold reduction of infectious GaLV-
TR LVs when using the T26S protease. Neverthe-
less, the modified glycoproteins GaLV-TRpro,
GaLV-TRsynt, and GaLV-TRDR allowed the
rescue of LV titers to levels identical to those ob-
tained in production using the wild-type prote-
ase. As expected, the production titers of LVs
pseudotyped with VSV-G were not affected bythe T26S protease, since this glycoprotein is not dependent on viral
protease cleavage to become fusogenically active.56 Together, these re-
sults demonstrate that the lower activity of T26S protease, despite not
affecting Gag-Pro-Pol production and its respective viral processing,
impairs the R-peptide cleavage of 4070A, RD114-TR, and GaLV-TR
glycoproteins, which directly affects the infectivity of LVs. Addition-
ally, since titers of these three LV pseudotypes were not similarly
affected, despite their common cytoplasmic tail (Figure 1B), it is
suggested that the glycoprotein sequence upstream regions
(ectodomain + transmembrane domain of transmembrane subunit
and surface subunit) may condition R-peptide recognition and cleav-
age by the viral protease. We hypothesize that the amino-acid differ-
ences on those glycoprotein upstream regions may promote differentlinical Development Vol. 15 December 2019 5
Molecular Therapy: Methods & Clinical Developmentconformational changes in the cytoplasmic tail of 4070A, RD114-TR,
and GaLV-TR glycoproteins, hampering the accessibility of viral pro-
tease to the respective cleavage sequences.
In this work, new GaLV-TR-derived glycoproteins were developed to
pseudotype LVs. Those glycoproteins allowed us to transiently pro-
duce a maximum LV titer of 6.0  106 TU , mL1, surpassing the
titers of LV pseudotypes with GaLV-TR, RD114-TR, or RDpro. Addi-
tionally, this work evidences that glycoprotein R-peptide cleavage ef-
ficiency by viral protease limits titers of infectious LVs. The new
GaLV-TRsynt and GaLV-TRpro are potential alternatives to both
VSV-G or RD114-derived glycoproteins for the establishment of
constitutively stable LV producer cell lines. Although further studies
are required, these novel envelopes show potential for the develop-
ment of alternative high-titer viral vector production platforms.
MATERIALS AND METHODS
Cell Culture
HEK293T cells (CRL-11268), obtained from the American Type Cul-
ture Collection (ATCC; Manassas, VA, USA), were used for LV pro-
duction and titration. Cells were cultured in DMEM (GIBCO, Life
Technologies, Paisley, UK) supplemented with 10% (v/v) fetal bovine
serum (FBS) (GIBCO). Cells were maintained in an incubator at 37C
with a humidified atmosphere of 7% CO2 in air. The trypan blue
exclusion method was used to assess cell concentration and viability.
Plasmids
Plasmid pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene #12252, kindly
provided by Dr. Didier Trono) codes for a SIN-LV genome carrying
a GFP as a reporter gene and was used as a transgene in all LV
production.
Plasmid pMDLg/pRRE57 (Addgene #12251, kindly provided by Dr.
Didier Trono) codes for HIV-1 Gag-Pro-Pol polyprotein. The
introduction of the T26S point mutation on the viral protease
sequence originated the pGP(T26S)P plasmid.50 Plasmid pRSV-
REV57 (Addgene #12253, kindly provided by Dr. Didier Trono) codes
for the second and third exons of HIV-1 rev. These plasmids coding
for the LV packaging functions were used in transient LV production.
Plasmids coding for envelope glycoproteins are as follows: pMD2.G
(Addgene #12259, kindly provided by Dr. Didier Trono) codes for
VSV-G; pCMV-GaLV-TR codes for a modified glycoprotein of the
GaLV SEATO strain and results from the removal of 19 nt prior to
the start codon of the GaLV glycoprotein from phGaLV10A1 by in-
verse PCR; phGaLV10A1 was kindly provided by Dr. Otto Merten
(Généthon, Évry, France); pCMV-RD114-TR codes for a modified
RD114 glycoprotein, amplified from the pLTR-RD114A19 plasmid
(Addgene #17576, kindly provided by Dr. Jakob Reiser) and cloned
into the vector resultant from phGaLV10A1 restriction with EcoRI
and KasI enzymes; pCMV-RDpro codes for RDpro43 glycoprotein,
which was chemically synthesized (GeneScript, Piscataway, NJ, USA)
and cloned into the vector resultant from phGaLV10A1 restriction
with EcoRI and KasI enzymes; pCMV-4070A codes for the ampho-6 Molecular Therapy: Methods & Clinical Development Vol. 15 Decembtropic MLV glycoprotein amplified from pMonoZeo-4070A50 and
cloned into the vector resultant from phGaLV10A1 restriction with
EcoRI and KasI enzymes; pCMV-GaLV-TRpro, pCMV-RD114-TRpro,
and pCMV-4070Apro code for the respective modified viral glycopro-
teins in which the viral protease cleavage sequence VQALVLTQ of
the 4070A glycoprotein cytoplasmic tail was replaced by that of the
HIV-1 Gag matrix-capsid, SQNYPIVQ, by inverse PCR from the
parental plasmids; pCMV-GaLV-TRsynt, pCMV-RD114-TRsynt, and
pCMV-4070Asynt code for the respective viral modified glycoproteins
in which the viral protease cleavage sequence VQALVLTQ of the
4070A glycoprotein cytoplasmic tail was replaced by synthetic peptide
GSGIFLETSL52 by performing two inverse PCRs from the parental
plasmids; pCMV-GaLV-TRDR, pCMV-RD114-TRDR, and pCMV-
4070ADR code for the respective truncated glycoproteins in which
the R-peptide was deleted from the cytoplasmic tail of the glycoproteins
and replaced by a STOP codon by inverse PCR.
The primers and templates used in plasmid constructions, as well as
the cloning strategies, are described in Table S1.
Transient LV Production
Transient LV production was performed by transfecting 293T cells as
describedbyTomás et al. (2018).50Briefly, 6 104 cells per square centi-
meterwere seeded in tissue cultureflasks and, 24hours later, transfected
using linear 25 kDa polyethyleneimine (PEI; Polysciences, Hirschberg
an der Bergstrasse, Germany) at a mass ratio of 1:1.5 (DNA:PEI),
with the respective plasmids. The amount of each viral component
per million cells was the following: 2.5 mg vector genome; 1 mg Gag-
Pro-Pol; 0.25mg Rev; 0.9mg envelope.Mediumwas exchanged 24 hours
after transfection. 24hours aftermediumexchange, the supernatantwas
collected, clarified at 0.45 mm, and stored at 80C.
Transducing LV Particle Titers
The transducing LV titer determination was performed by trans-
ducing 293T cells with the produced supernatants followed by flow
cytometry analysis for GFP expression, as described by Tomás et al.
(2018).50 The concentration of LV TUs (TU , mL1) was calculated
using the following equation:
Titer

TU
mL

=
% of GFP positive cells
100
 dilution factor
volume of transduction
 n of cells at transduction time:
Physical LV Particle Titers
The concentration of p24 LV protein in supernatants was determined
by a p24 ELISA using the INNOTEST HIV Antigen mAb (Fujirebio
Diagnostics, Malvern, PA, USA), following the manufacturer’s in-
structions. It was assumed that 1 ng p24 corresponds to 1.25  107
physical particles.58 The titer of LV PPs (PP , mL1) was estimated
using the following equation:
Titer

PP
mL

= ½p24 protein  12500000:er 2019
www.moleculartherapy.orgStatistical Analysis
To assess the significance of differences seen among titers of LV-pseu-
dotype production, statistical analysis was used to evaluate data from
multiple experiments using GraphPad Prism v5 (GraphPad Software,
San Diego, CA, USA). For the comparison of LV titers differences on
p values <0.05, using unpaired Student t test (two-tailed), were
considered significant.
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